Insider Selling: Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Sells 1,500 Shares of Stock

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Bruce C. Cozadd sold 1,500 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total transaction of $185,145.00. Following the completion of the transaction, the chief executive officer now directly owns 425,525 shares in the company, valued at $52,522,550.75. This represents a 0.35 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Jazz Pharmaceuticals Stock Up 1.0 %

Jazz Pharmaceuticals stock traded up $1.26 during trading hours on Monday, hitting $121.82. The company had a trading volume of 572,637 shares, compared to its average volume of 561,950. The firm’s fifty day moving average is $121.03 and its 200-day moving average is $113.68. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. Jazz Pharmaceuticals plc has a fifty-two week low of $99.06 and a fifty-two week high of $134.17. The firm has a market capitalization of $7.36 billion, a P/E ratio of 17.16, a price-to-earnings-growth ratio of 1.04 and a beta of 0.56.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on JAZZ shares. Royal Bank of Canada restated an “outperform” rating and issued a $179.00 price objective on shares of Jazz Pharmaceuticals in a report on Tuesday, December 10th. HC Wainwright restated a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Needham & Company LLC reiterated a “buy” rating and issued a $207.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. TD Cowen reduced their target price on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $140.00 target price on shares of Jazz Pharmaceuticals in a research report on Monday, September 9th. Two equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $177.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Itau Unibanco Holding S.A. acquired a new stake in shares of Jazz Pharmaceuticals during the 2nd quarter valued at about $29,000. EverSource Wealth Advisors LLC raised its position in Jazz Pharmaceuticals by 55.1% during the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock valued at $30,000 after acquiring an additional 97 shares in the last quarter. GAMMA Investing LLC lifted its stake in Jazz Pharmaceuticals by 41.3% in the third quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock valued at $46,000 after acquiring an additional 121 shares during the last quarter. Venturi Wealth Management LLC grew its position in Jazz Pharmaceuticals by 577.0% in the third quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock worth $92,000 after acquiring an additional 704 shares in the last quarter. Finally, Versant Capital Management Inc increased its stake in shares of Jazz Pharmaceuticals by 56.7% during the 4th quarter. Versant Capital Management Inc now owns 967 shares of the specialty pharmaceutical company’s stock worth $119,000 after purchasing an additional 350 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.